Sandoz invests in major expansion of global headquarters in Holzkirchen, Germany

• Expected investment will amount to approximately USD 50m
• Decision to expand underlines confidence in growth potential of business
• Modern campus facility will promote more collaborative ways of working

Holzkirchen, August 29, 2017 — Sandoz, the generic pharmaceuticals and biosimilars division of Novartis, announced today that it will further expand its global headquarters in Holzkirchen, near Munich. The expected investment will amount to approximately USD 50m.

Sandoz will begin construction of two additional office buildings at the company's global headquarters at Industriestrasse 18, each of which will create space for around 250 new workplaces. The new buildings are expected to be completed by end of 2018.

"Sandoz is a global leader in generics and the worldwide #1 in biosimilars.” said Sandoz CEO Richard Francis. “We are also the market leader in Germany, our second largest market globally, and Europe overall. This decision to expand our headquarters underlines our confidence in the growth potential of our business.”

He added: “The additional buildings will allow us to consolidate office space and, at the same time, create room for the further growth of our company. With its proximity to both Munich and the Alps, as well as its good traffic connections and infrastructure, Holzkirchen is an attractive location for Sandoz with a great deal to offer both current and future employees."

Sandoz will also use the construction of the new buildings as an opportunity to create a modern campus, which will allow employees to work in a more collaborative and flexible way. Sandoz has grown steadily in recent years and today employs more than 1800 employees at its two existing building complexes at Industriestrasse 18 and 25, as well as various leased offices in Holzkirchen and the south of Munich.

This expansion confirms the long-term commitment of Novartis to the Holzkirchen site. The site houses the Sandoz global head office, regional and local business management, as well as Research & Development, production and service facilities.

About Sandoz
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached well over 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.

# # #

For further inquiries: